An Open-Label Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies

Grants and Contracts Details

StatusFinished
Effective start/end date5/15/097/31/17

Funding

  • Millennium Pharmaceuticals Inc: $186,795.00